Compare · FLGT vs HUM
FLGT vs HUM
Side-by-side comparison of Fulgent Genetics Inc. (FLGT) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGT and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.96B, about 86.2x FLGT ($545.1M).
- Over the past year, FLGT is down 7.8% and HUM is up 30.8% - HUM leads by 38.6 points.
- HUM has hit the wire 6 times in the past 4 weeks while FLGT has been quiet.
- HUM has more recent analyst coverage (25 ratings vs 9 for FLGT).
- Company
- Fulgent Genetics Inc.
- Humana Inc.
- Price
- $19.80-0.95%
- $391.01+0.56%
- Market cap
- $545.1M
- $46.96B
- 1M return
- +0.92%
- +0.60%
- 1Y return
- -7.78%
- +30.85%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 0
- 6
- Recent ratings
- 9
- 25
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest FLGT
- SEC Form 10-Q filed by Fulgent Genetics Inc.
- Fulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Fulgent Reports Second Quarter 2026 Financial Results
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,747 shares, decreasing direct ownership by 0.76% to 359,798 units (SEC Form 4) (withholding obligation)
- President and COO Xie Jian covered exercise/tax liability with 4,361 shares, decreasing direct ownership by 1% to 363,244 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Gao Hanlin covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 0.17% to 988,729 units (SEC Form 4) to satisfy withholding obligation
- Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- President and COO Xie Jian sold $38,382 worth of shares (2,146 units at $17.89), decreasing direct ownership by 0.58% to 367,605 units (SEC Form 4) (tax withholding)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.57% to 362,545 units (SEC Form 4) to cover taxes
- Chief Scientific Officer Gao Hanlin sold $30,191 worth of shares (1,688 units at $17.89), decreasing direct ownership by 0.17% to 990,374 units (SEC Form 4) (withholding obligation)
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)